Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology

The Life Sciences team advised Myricx Bio on its agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion in upfront cash plus potential milestone payments. The acquisition brings together Novartis' oncology expertise with Myricx Bio's novel antibody-drug conjugate (ADC) assets and first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform to advance the development of next-generation oncology therapeutics with potential application across multiple solid tumor types. The transaction is expected to close in the second half of 2026, subject to customary closing conditions, including regulatory approvals.

Myricx Bio is a private biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. It has pioneered the development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibition of N-myristoyltransferase (NMT). A spin-out from Imperial College London and the Francis Crick Institute, Myricx Bio is headquartered in London with teams based in the UK and USA. Investors include Abingworth, Brandon Capital Partners, British Business Bank, Cancer Research Horizons, Eli Lilly, Novo Holdings, and Sofinnova Partners.

The Goodwin team was led by Mitch Bloom, Adam Dilluvio, Kenny Walker-Durrant, Amine Assouad, Duy Le, Rachel Conder, Morag Peberdy, Lucy Sharples, Arman Oruc, Kevin Walsh, Vicky Ling, Anna Humphrey, Grace Wirth, Elizabeth Mulkey, Dasol Lee, Rahat Tariq, Alex Fisher, Dan Karelitz, Dulcie Daly, Chase Gorland, and Sarah Jordan.

For more information, please read the press release.